Stanford V
Checked 2026-09-09
Historical 12-week regimen with consolidative radiotherapy for advanced Hodgkin lymphoma; not superior to ABVD in the US Intergroup E2496 trial
Also called STANFORD V.
One cycle
every 28 days × 3 · about 12 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Doxorubicin Cytotoxic chemotherapy (anthracycline) | 25 mg/m² | IV | D1, 15 | |
Vinblastine Vinca alkaloid (microtubule inhibitor) | 6 mg/m² | IV | D1, 15 | |
Mechlorethamine Alkylating agent (nitrogen mustard); intravenous and topical gel | 6 mg/m² | IV | D1 | |
Vincristine Vinca alkaloid (microtubule inhibitor) | 1.4 mg/m² (maximum 2 mg) | IV | D8, 22 | |
Bleomycin Glycopeptide antibiotic (DNA-cleaving) | 5 units/m² | IV | D8, 22 | |
Etoposide Topoisomerase II inhibitor (podophyllotoxin derivative) | 60 mg/m² | IV | D15, 16 | |
Prednisone Glucocorticoid | 40 mg/m² every other day | Oral | D1-28 |
Cycles
3 (12 weeks), then radiotherapy to sites over 5 cm
28-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Notes
- Designed at Stanford to cut cumulative doxorubicin and bleomycin by shortening chemotherapy and relying on radiotherapy; E2496 showed no advantage over ABVD, so it is rarely used now.
- Mechlorethamine has been in and out of supply; cyclophosphamide was substituted in some centres.
Used in
Source
Gordon (E2496), JCO 2013: ABVD versus Stanford V in locally extensive and advanced Hodgkin lymphoma
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
ABVD
Classical Hodgkin lymphoma: 2-4 cycles early stage (PET-adapted), 6 cycles advanced stage
every 28 days × 2-6
BV-AVD
Stage III-IV classical Hodgkin lymphoma
every 28 days × 6
N-AVD (nivolumab + AVD)
Stage III-IV classical Hodgkin lymphoma, age 12 and above
every 28 days × 6
ICE
Relapsed or refractory aggressive lymphoma and Hodgkin lymphoma, salvage and stem cell mobilisation before autologous transplant (R-ICE when rituximab is added)
every 14 days × 2-3
Escalated BEACOPP
Advanced-stage classical Hodgkin lymphoma in fit patients under 60, PET-adapted to 4-6 cycles
every 21 days × 4-6
MOPP
Historical: the first curative combination chemotherapy for advanced Hodgkin lymphoma (1960s to 1980s), replaced by ABVD
every 28 days × 6
ABVE-PC
Children and adolescents with intermediate- and high-risk Hodgkin lymphoma in Children's Oncology Group trials, response-adapted with or without radiotherapy
every 21 days × 4-5
OEPA (vincristine, etoposide, prednisone, doxorubicin)
Induction for children and adolescents with Hodgkin lymphoma in the European EuroNet-PHL protocols; OPPA (procarbazine instead of etoposide) was the earlier version used in girls
every 28 days × 2